<DOC>
	<DOCNO>NCT01516346</DOCNO>
	<brief_summary>The main objective test effect prolong therapy ( 24 week ) isosorbide dinitrate Â± hydralazine arterial wave reflection ( primary endpoint ) . Secondary endpoint include leave ventricular ( LV ) mass , fibrosis diastolic function ) exercise capacity ( assessed via 6-minute walk test ) patient Heart Failure Preserved Ejection Fraction ( HFPEF ) . We also test hypothesis reduction arterial wave reflection induce vasoactive therapy correlate improvement exercise capacity , LV mass , fibrosis diastolic function . Finally , ass whether hemodynamic response acute dose sublingual nitroglycerin ( NTG ) predict sustain change reflect wave hemodynamic parameter response chronic vasodilator therapy .</brief_summary>
	<brief_title>Vasodilator Therapy Heart Failure Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Vasodilator Agents</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>1 . Previous clinical diagnosis heart failure current New York Heart Association Class IIIV symptom . 2 . LV ejection fraction &gt; 50 % clinically indicate echocardiogram ventriculogram within 12 month prior consent , absence change cardiovascular status , assess principal investigator . 3 . Must least one follow within 12 month prior consent 1 . Hospitalization decompensated HF 2 . Acute treatment HF intravenous loop diuretic hemofiltration . 3 . Chronic treatment loop diuretic control HF symptom . 4 . Chronic diastolic dysfunction echocardiography evidence left atrial enlargement least stage II diastolic dysfunction . 5 . Documentation elevate NTpro BNP level natriuretic peptide marker ( BNP , ANP ) accord laboratory assay upper limit normal previous year . 4 . Stable medical therapy define : 1 . No addition removal ACE , ARB , betablockers , calcium channel blocker ( CCBs ) 30 day . 2 . No change dosage ACE , ARBs , betablockers CCBs 100 % 30 day . 3 . No change diuretic dose 10 day . 1 . Rhythm sinus rhythm ( i.e. , atrial fibrillation ) . 2 . Neuromuscular , orthopedic noncardiac condition prevents patient walk hallway . 3 . Noncardiac condition limit life expectancy le one year , per physician judgment . 4 . Current anticipated future need nitrate therapy . 5 . Valve disease ( &gt; mild aortic mitral stenosis ; &gt; moderate aortic mitral regurgitation ) . 6 . Hypertrophic cardiomyopathy . 7 . Known infiltrative inflammatory myocardial disease ( amyloid , sarcoid ) . 8 . Pericardial disease . 9 . Primary pulmonary arteriopathy . 10 . Have experience myocardial infarction unstable angina , undergone percutaneous transluminal coronary angiography ( PTCA ) coronary artery bypass grafting ( CABG ) within 60 day prior consent , require either PTCA CABG time consent . 11 . Other clinically important cause dyspnea morbid obesity significant lung disease define clinical judgment use steroid oxygen lung disease . 12 . Systolic blood pressure &lt; 110 mmHg &gt; 180 mm Hg . 13 . Diastolic blood pressure &lt; 40 mmHg &gt; 100 mmHg . 14 . Resting heart rate ( HR ) &gt; 100 bpm . 15 . A history reduce ejection fraction ( EF &lt; 50 % ) . 16 . Severe renal dysfunction ( estimate GFR &lt; 30 ml/min/1.73m2 modify MDRD equation ) GFR ( mL/min/1.73 m2 ) = 175 x ( Scr ) 1.154 x ( Age ) 0.203 x ( 0.742 female ) x ( 1.210 African American ) ( conventional unit ) , would impede safe administration gadolinium MRI study contrast . 17 . Hemoglobin &lt; 10 g/dL . 18 . Patients know severe liver disease ( AST &gt; 3x normal , alkaline phosphatase bilirubin &gt; 2x normal ) . 19 . Patients clinically indicate stress test demonstrating significant ischemia within year enrollment follow percutaneous surgical revascularization . 20 . Listed cardiac transplantation . 21 . Allergy isosorbide dinitrate hydralazine . 22 . Current therapy phosphodiesterase inhibitor , sildenafil , vardenafil tadalafil , since combination nitrate phosphodiesterase inhibitor result severe hypotension . 23 . We also exclude patient suitable candidate cardiac MRI virtue follow absolute relative contraindication : ( ) Central nervous system aneurysm clip ; ( ii ) Implanted neural stimulators ; ( iii ) Implanted cardiac pacemaker defibrillator ; ( iv ) Cochlear implant ; ( v ) Ocular foreign body ( e.g . metal shaving ) ; ( vi ) Other implanted medical device : ( e.g . drug infusion port ) ; ( vii ) Insulin pump ; ( viii ) Metal shrapnel bullet ; ( ix ) Claustrophobia ; ( x ) Extreme obesity render patient unable fit narrowbore scanner ; ( xi ) Unwillingness patient undergo cardiac MRI . All patient metallic implant individually evaluate prior MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Heart failure preserve ejection fraction ( HFpEF )</keyword>
	<keyword>Vasodilators</keyword>
	<keyword>Isosorbide dinitrate</keyword>
	<keyword>Hydralazine</keyword>
	<keyword>wave reflection</keyword>
	<keyword>arterial stiffness</keyword>
	<keyword>hemodynamics</keyword>
</DOC>